Open AccessKL-6 as a Biomarker of Interstitial Lung Disease Development in Patients with Sjögren Syndrome: A Retrospective Case–Control Study
Author(s) -
Yu-Hsiang Chiu,
ChenChih Chu,
ChunChi Lu,
FengCheng Liu,
Shin-En Tang,
Shi-Jye Chu,
Shih-Ming Kuo,
Chen Hc
Publication year - 2022
Publication title -
journal of inflammation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.656
H-Index - 33
ISSN - 1178-7031
DOI - 10.2147/jir.s352085
Subject(s) - medicine , interstitial lung disease , biomarker , gastroenterology , immunoassay , lung , antibody , immunology , biochemistry , chemistry
Krebs von den Lungen-6 (KL-6) is expressed on regenerating type II pneumocytes and has been recognized as biomarkers in interstitial lung disease (ILD). We aim to identify the role of the serum KL-6 level in patients with newly diagnosed Sjögren syndrome (SS), as well as the correlation between the immunoassays.